Cerca Magnetics Limited

Cerca Magnetics operates at the intersection of neuroimaging, quantum sensing, medical devices and research instrumentation. Its central differentiation is the integration of optically pumped magnetometers, wearable MEG helmets, magnetic shielding and background-field control into a single functional brain-imaging workflow. Compared with conventional fixed MEG installations, its lightweight and ergonomic approach is designed to support more natural movement and more realistic experimental conditions. The company also offers magnetically shielded rooms, signal-acquisition and field-control software, phantom devices and system-integration services, giving it a broader delivery scope than a sensor-only supplier. Its target market currently appears to be research institutions and clinical-development programs rather than approved diagnostic care: the technology is described as research-use-only and has no stated medical or regulatory approvals. The £5.14 million Series A and £4.10 million Ministry of Defence grant nevertheless indicate traction across both commercial neurotechnology and government-backed applied research.

Cerca Magnetics has moved from founding-stage technology development toward commercialization and clinical translation. Founded on Jul 24, 2020, the company combines founders with backgrounds in physics, neuroscience and scientific advising, while its current employee range is listed at 11–50 people. That was followed by a £3.8 million, or $5.14 million, Series A led by Guinness Ventures on Apr 21, 2026, bringing recorded funding to approximately $9.24 million across two rounds. The financing sequence marks an inflection point: the company is using non-dilutive support for applied safety work while raising equity to move OPM-MEG toward clinical deployment. Product breadth has also expanded beyond a wearable scanner to include sensor-equipped helmets, magnetic shielding, field-control systems and integration services. Hiring for a Design Assurance Engineer suggests preparation for more formalized product-quality and regulated-development processes, although no regulatory approval or confirmed hospital deployment is yet documented.